Search Results
in people, suggesting a causal relationship between hypercalcemia and the development of AP at least in people. 7 , 8 The effect of the resolution of hypercalcemia on pancreatic lipase (cPLI) concentrations in dogs is unknown. Humans with recurrent
the body, and serum lipase activity may be affected by many extrapancreatic conditions. 1,5–7 An ELISA for the measurement of cPLI concentrations has been developed and analytically validated. 8 In that study, 8 a reference range of 2.2 to 102.1 μg
adaptation or function. 7 Compared with total serum lipase activity, assessment of serum cPLI concentration appears to have improved sensitivity and specificity as a commercially available laboratory test for diagnosis of pancreatitis in dogs; moreover
Introduction Measurements of serum concentrations of cobalamin (vitamin B12), folate (vitamin B9), cPLI, and cTLI are widely used as minimally invasive tools to diagnose and monitor small intestinal and exocrine pancreatic disease in dogs. 1
Abstract
Objective—To develop and validate a radioimmunoassay (RIA) for measuring canine pancreatic lipase immunoreactivity (cPLI) in serum obtained from dogs.
Sample Population—Serum samples from 47 healthy dogs.
Procedures—Canine pancreatic lipase (cPL) was purified from pancreatic specimens of dogs. Antibodies against cPL were raised in rabbits and purified by use of affinity chromatography. A tracer was produced by iodination of cPL with 125I. An RIA was established and validated by determination of sensitivity, working range, dilutional parallelism, spiking recovery, and intra- and interassay variability. A reference range for cPLI in serum was established by use of the central 95th percentile for samples obtained from 47 healthy dogs.
Results—Sensitivity and upper limit of the working range were 0.88 and 863 µg/L, respectively. Observed-to-expected ratios for serial dilutions ranged from 84.9 to 116.5% for 4 samples. Observedto- expected ratios for spiking recovery ranged from 82.8 to 128.6% for 4 samples. Coefficients of variation for intra-assay variability for 4 serum samples were 18.3, 4.2, 3.5, and 8.9%, whereas interassay coefficients of variation were 29.2, 6.2, 3.9, and 4.4%, respectively. The reference range was 4.4 to 276.1 µg/L.
Conclusions and Clinical Relevance—We conclude that the RIA described is sensitive, linear, accurate, precise, and reproducible, with limited accuracy in the high end of the working range and limited precision and reproducibility in the low end of the working range. Additional studies are needed to evaluate whether this degree of accuracy, precision, and reproducibility will negatively impact clinical use of this assay. (Am J Vet Res 2003;64:1237–1241)
bromide concentration was determined with a spectrometer. i Serum cPLI was determined with a commercial ELISA. j A conventional enzymatic method k was used to measure serum bile acids concentrations before and after a meal in 3 dogs with high serum
diagnosed in Miniature Schnauzers on the basis of the following criteria: clinical signs compatible with a diagnosis of pancreatitis (eg, vomiting, anorexia, abdominal pain, or a combination of these), an increase in serum cPLI concentration (cPLI
is low as well. 6 Abdominal ultrasonography is highly specific when stringent criteria are used, but the highest sensitivity reported for dogs is only 68%. 6 A more recently developed test, the cPLI assay, was designed to exclusively measure the
–21 , a Serum cPLI concentration is a highly sensitive and specific indicator of pancreatitis, and high cPLI concentration in dogs with IBD has been shown to be associated with a poor prognosis. 22,23 α 1 -Proteinase inhibitor is present in plasma
findings, ultrasonographic findings, serum cPLI, and histologic findings and if other possible conditions had been ruled out on the basis of results of a CBC and serum biochemical panel. Information was obtained only for the first visit of each case dog
